Overview

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label

Status:
Terminated

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

Summary

Phase 2 multicenter, controlled, randomized, double-blind study to evaluate the efficacy and safety of ficlatuzumab versus placebo when administered with erlotinib in subjects with previously untreated metastatic EGFR-mutated NSCLC and BDX004 Positive Label.

Phase:

Phase 2

Details

Lead Sponsor:

AVEO Pharmaceuticals, Inc.

Collaborators:

Biodesix Inc.
Biodesix, Inc.

Treatments:

Erlotinib Hydrochloride